Gastrointestinal Therapeutics Market size is expected to reach US$ 78.58 Bn. by 2030, at a CAGR of 5.59% during the forecast period. The report has covered Country Market trends with competitive landscape.Global Gastrointestinal Therapeutics Market Overview:
Rising acceptance of biologics for the treatment of gastrointestinal diseases is the main driver of the market. A wide range of new generation therapeutics aims at comprising novel small molecules & cellular therapy are presently under investigation. These contain tofacitinib, & vedolizumab. This arrival is expected to be a significance of high occurrence of gastrointestinal diseases worldwide. Vedolizumab is developing as a first-line biologic treatment for Crohn’s disease. Now, the U.S. FDA has accepted Humira, Amjevita, Cimzia, Remicade, & Entyvio for the cure of Crohn’s disease.To know about the Research Methodology :- Request Free Sample Report The analysis shows that biologics displays superior long-term efficiency. According to the analysis led by University of Chicago, usage of biologics has caused in a total reduction in the number of surgeries by about 39.65%, extra room stays by 59.87%, & hospitalizations by 49.76%. The generic segment is anticipated to grow at an exponential rate during the forecast period because steady finishes of patents, cost-effectiveness of generics, & initiatives by government administrations for endorsing usage of generics in developing economies. In addition, key pharmaceutical players are steadily determined to launch generic versions of their branded complements to recover losses affected by patent expiration. Branded drug producers & generic producing companies are cooperating for manufacturing generic drugs after patent expiry, which is expected to increase the development of generics. In addition, key companies are gradually focusing on emerging generics because of the rise in off-patented drugs in the market. However, promotion exclusivity given by the FDA to patent holders for dissimilar indications is expected to hinder market development to a slight extent. The others segment accounted for the major share by application in the year 2023. The large share can be attributed to an extensive range of applications for which gastrointestinal drugs have been used steadily over the past few years. Frequent number of drug launches is also responsible for improved scope for development. Ulcerative colitis accounted for the second-largest share in the market in the year 2023. Progress of this segment can be attributed to easy accessibility of drugs to treat this disorder. The segment is also expected to grow at a substantial rate thanks to high clinical urgency to control rising prevalence of ulcerative colitis. This high occurrence is owing to poor prognosis & consumption of unhealthy food, which may result in high possibility of disease recurrence. In 2023, retail pharmacy accounted for the leading share in terms of distribution channel due to high affordability & availability to retail stores. As number of treatment medicines being reimbursed is growing, it is inspiring patients to buy medicines from retail pharmacies. Retail pharmacists also suggest drug alternates that prevent adverse drug interactions. These influences are likely to increase customer preference toward retail stores. In case retail pharmacists have any worries concerning prescribed medicines, they suggest substitutes for the same, thus ensuring higher safety. Start of pharmacy chains like CVS Health is a key supplier to the share of the retail segment. Acceptance of digitalized systems in retail pharmacies to decrease risk of mistakes in prescriptions is also expected to fuel development the forecast period. The North America market accounted for the major share of xx% in 2023 and is anticipated to keep its position during the forecast period. This extensive share is attributed to extraordinary change in lifestyle, causing in greater occurrence of gastrointestinal diseases. Moreover, occurrence of government initiatives expected at preventing as well as treating gastrointestinal diseases is expected to drive the market towards north. For example, the Integrated Global Action Plan for Diarrhoea by UNICEF & WHO objects at reducing avoidable childhood deaths as a result of diarrhea by providing interventions & services to increase awareness & deliver access to treatment & preventive measures.
Competitive Landscape:
The objective of the report is to present a comprehensive analysis of the Global Gastrointestinal Therapeutics Market including all the stakeholders of the industry. The past and current status of the industry with forecasted Market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes Market leaders, followers and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the Market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Gastrointestinal Therapeutics Market dynamics, structure by analyzing the Market segments and project the Global Gastrointestinal Therapeutics Market size. Clear representation of competitive analysis of key players by Type, price, financial position, Raw material portfolio, growth strategies, and regional presence in the Global Gastrointestinal Therapeutics Market make the report investor’s guide.Scope of Global Gastrointestinal Therapeutics Market: Inquire before buying
Global Gastrointestinal Therapeutics Market Report Coverage Details Base Year: 2023 Forecast Period: 2024-2030 Historical Data: 2018 to 2023 Market Size in 2023: US $ 53.69 Bn. Forecast Period 2024 to 2030 CAGR: 5.59% Market Size in 2030: US $ 78.58 Bn. Segments Covered: by Type Branded Generics by Route of Administration Oral Intravenous Others by Application Ulcerative Colitis Crohn’s Disease GERD Others by Distribution Channel Hospital Pharmacies Retail Pharmacies Online Pharmacies Global Gastrointestinal Therapeutics Market, by Region
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) North America (United States, Canada and Mexico) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Key Players
1. Abbott Laboratories 2. Allergan plc 3. AstraZeneca 4. Bayer AG 5. GlaxoSmithKline plc 6. Janssen Pharmaceuticals 7. Takeda Pharmaceuticals 8. Valeant Pharmaceuticals 9. Pfizer 10. AbbVie, Inc. 11. AstraZeneca 12. Shire 13. Valeant (Salix Pharmaceuticals) 14. Takeda Pharmaceutical Company Limited 15. Eisai Co. Ltd. 16. Johnson & Johnson Private Limited 17. Astellas Pharma Inc. 18. Novo Nordisk A/S 19. Sanofi S.A.Frequently Asked Questions:
1. Which region has the largest share in Global Gastrointestinal Therapeutics Market? Ans: North America region holds the highest share in 2023. 2. What is the growth rate of Global Gastrointestinal Therapeutics Market? Ans: The Global Gastrointestinal Therapeutics Market is growing at a CAGR of 5.59% during forecasting period 2024-2030. 3. What is scope of the Global Gastrointestinal Therapeutics market report? Ans: Global Gastrointestinal Therapeutics Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Gastrointestinal Therapeutics market? Ans: The important key players in the Global Gastrointestinal Therapeutics Market are – Abbott Laboratories, Allergan plc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Janssen Pharmaceuticals, Takeda Pharmaceuticals, Valeant Pharmaceuticals, Pfizer, AbbVie, Inc., AstraZeneca, Shire, Valeant (Salix Pharmaceuticals), Takeda Pharmaceutical Company Limited, Eisai Co. Ltd., Johnson & Johnson Private Limited, Astellas Pharma Inc., Novo Nordisk A/S, and Sanofi S.A. 5. What is the study period of this market? Ans: The Global Gastrointestinal Therapeutics Market is studied from 2023 to 2030.
Global Gastrointestinal Therapeutics Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Gastrointestinal Therapeutics Market Size, by Market Value (US$ Mn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Gastrointestinal Therapeutics Market Analysis and Forecast 7. Global Gastrointestinal Therapeutics Market Analysis and Forecast, by Type 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Gastrointestinal Therapeutics Market Value Share Analysis, by Type 7.4. Global Gastrointestinal Therapeutics Market Size (US$ Mn) Forecast, by Type 7.5. Global Gastrointestinal Therapeutics Market Analysis, by Type 7.6. Global Gastrointestinal Therapeutics Market Attractiveness Analysis, by Type 8. Global Gastrointestinal Therapeutics Market Analysis and Forecast, by Route of Administration 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Gastrointestinal Therapeutics Market Value Share Analysis, by Route of Administration 8.4. Global Gastrointestinal Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration 8.5. Global Gastrointestinal Therapeutics Market Analysis, by Route of Administration 8.6. Global Gastrointestinal Therapeutics Market Attractiveness Analysis, by Route of Administration 9. Global Gastrointestinal Therapeutics Market Analysis and Forecast, by Application 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Gastrointestinal Therapeutics Market Value Share Analysis, by Application 9.4. Global Gastrointestinal Therapeutics Market Size (US$ Mn) Forecast, by Application 9.5. Global Gastrointestinal Therapeutics Market Analysis, by Application 9.6. Global Gastrointestinal Therapeutics Market Attractiveness Analysis, by Application 10. Global Gastrointestinal Therapeutics Market Analysis and Forecast, by Distribution Channel 10.1. Introduction and Definition 10.2. Key Findings 10.3. Global Gastrointestinal Therapeutics Market Value Share Analysis, by Distribution Channel 10.4. Global Gastrointestinal Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel 10.5. Global Gastrointestinal Therapeutics Market Analysis, by Distribution Channel 10.6. Global Gastrointestinal Therapeutics Market Attractiveness Analysis, by Distribution Channel 11. Global Gastrointestinal Therapeutics Market Analysis and Forecast, by Region 11.1. Introduction and Definition 11.2. Key Findings 11.3. Global Gastrointestinal Therapeutics Market Value Share Analysis, by Region 11.4. Global Gastrointestinal Therapeutics Market Size (US$ Mn) Forecast, by Region 11.5. Global Gastrointestinal Therapeutics Market Analysis, by Region 12. Global Gastrointestinal Therapeutics Market Analysis 12.1. Key Findings 12.2. Global Gastrointestinal Therapeutics Market Overview 12.3. Global Gastrointestinal Therapeutics Market Forecast, by Type 12.3.1. Branded 12.3.2. Generics 12.4. Global Gastrointestinal Therapeutics Market Forecast, by Route of Administration 12.4.1. Oral 12.4.2. Intravenous 12.4.3. Others 12.5. Global Gastrointestinal Therapeutics Market Forecast, by Application 12.5.1. Ulcerative Colitis 12.5.2. Crohn’s Disease 12.5.3. GERD 12.5.4. Others 12.6. Global Gastrointestinal Therapeutics Market Forecast, by Distribution Channel 12.6.1. Hospital Pharmacies 12.6.2. Retail Pharmacies 12.6.3. Online Pharmacies 12.7. Global Gastrointestinal Therapeutics Market Forecast, by Region 12.7.1. North America 12.7.2. Europe 12.7.3. Asia-Pacific 12.7.4. MEA & Africa 12.7.5. Latin America 12.8. PEST Analysis 12.9. Key Trends 12.10. Key Developments 13. North-America Gastrointestinal Therapeutics Market Analysis 13.1. Key Findings 13.2. North-America Gastrointestinal Therapeutics Market Forecast, by Type 13.2.1. Branded 13.2.2. Generics 13.3. North-America Gastrointestinal Therapeutics Market Forecast, by Route of Administration 13.3.1. Oral 13.3.2. Intravenous 13.3.3. Others 13.4. North-America Gastrointestinal Therapeutics Market Forecast, by Application 13.4.1. Ulcerative Colitis 13.4.2. Crohn’s Disease 13.4.3. GERD 13.4.4. Others 13.5. North-America Gastrointestinal Therapeutics Market Forecast, by Distribution Channel 13.5.1. Hospital Pharmacies 13.5.2. Retail Pharmacies 13.5.3. Online Pharmacies 13.6. North-America Gastrointestinal Therapeutics Market Forecast, by Country 13.6.1. US 13.6.2. Canada 13.7. US Gastrointestinal Therapeutics Market Forecast, by Type 13.7.1. Branded 13.7.2. Generics 13.8. US Gastrointestinal Therapeutics Market Forecast, by Route of Administration 13.8.1. Oral 13.8.2. Intravenous 13.8.3. Others 13.9. US Gastrointestinal Therapeutics Market Forecast, by Application 13.9.1. Ulcerative Colitis 13.9.2. Crohn’s Disease 13.9.3. GERD 13.9.4. Others 13.10. US Gastrointestinal Therapeutics Market Forecast, by Distribution Channel 13.10.1. Hospital Pharmacies 13.10.2. Retail Pharmacies 13.10.3. Online Pharmacies 13.11. Canada Gastrointestinal Therapeutics Market Forecast, by Type 13.11.1. Branded 13.11.2. Generics 13.12. Canada Gastrointestinal Therapeutics Market Forecast, by Route of Administration 13.12.1. Oral 13.12.2. Intravenous 13.12.3. Others 13.13. Canada Gastrointestinal Therapeutics Market Forecast, by Application 13.13.1. Ulcerative Colitis 13.13.2. Crohn’s Disease 13.13.3. GERD 13.13.4. Others 13.14. Canada Gastrointestinal Therapeutics Market Forecast, by Distribution Channel 13.14.1. Hospital Pharmacies 13.14.2. Retail Pharmacies 13.14.3. Online Pharmacies 13.15. PEST Analysis 13.16. Key Trends 13.17. Key Developments 14. Europe Gastrointestinal Therapeutics Market Analysis 14.1. Key Findings 14.2. Europe Gastrointestinal Therapeutics Market Overview 14.3. Global Gastrointestinal Therapeutics Market Forecast, by Type 14.3.1. Branded 14.3.2. Generics 14.4. Europe Gastrointestinal Therapeutics Market Forecast, by Route of Administration 14.4.1. Oral 14.4.2. Intravenous 14.4.3. Others 14.5. Europe Gastrointestinal Therapeutics Market Forecast, by Application 14.5.1. Ulcerative Colitis 14.5.2. Crohn’s Disease 14.5.3. GERD 14.5.4. Others 14.6. Europe Gastrointestinal Therapeutics Market Forecast, by Distribution Channel 14.6.1. Hospital Pharmacies 14.6.2. Retail Pharmacies 14.6.3. Online Pharmacies 14.7. Europe Gastrointestinal Therapeutics Market Forecast, by Country 14.7.1. UK 14.7.2. France 14.7.3. Germany 14.7.4. Russia 14.7.5. Italy 14.7.6. Rest of Europe 14.8. UK Gastrointestinal Therapeutics Market Forecast, by Type 14.8.1. Branded 14.8.2. Generics 14.9. UK Gastrointestinal Therapeutics Market Forecast, by Route of Administration 14.9.1. Oral 14.9.2. Intravenous 14.9.3. Others 14.10. UK Gastrointestinal Therapeutics Market Forecast, by Application 14.10.1. Ulcerative Colitis 14.10.2. Crohn’s Disease 14.10.3. GERD 14.10.4. Others 14.11. UK Gastrointestinal Therapeutics Market Forecast, by Distribution Channel 14.11.1. Hospital Pharmacies 14.11.2. Retail Pharmacies 14.11.3. Online Pharmacies 14.12. France Gastrointestinal Therapeutics Market Forecast, by Type 14.12.1. Branded 14.12.2. Generics 14.13. France Gastrointestinal Therapeutics Market Forecast, by Route of Administration 14.13.1. Oral 14.13.2. Intravenous 14.13.3. Others 14.14. France Gastrointestinal Therapeutics Market Forecast, by Application 14.14.1. Ulcerative Colitis 14.14.2. Crohn’s Disease 14.14.3. GERD 14.14.4. Others 14.15. France Gastrointestinal Therapeutics Market Forecast, by Distribution Channel 14.15.1. Hospital Pharmacies 14.15.2. Retail Pharmacies 14.15.3. Online Pharmacies 14.16. Germany Gastrointestinal Therapeutics Market Forecast, by Type 14.16.1. Branded 14.16.2. Generics 14.17. Germany Gastrointestinal Therapeutics Market Forecast, by Route of Administration 14.17.1. Oral 14.17.2. Intravenous 14.17.3. Others 14.18. Germany Gastrointestinal Therapeutics Market Forecast, by Application 14.18.1. Ulcerative Colitis 14.18.2. Crohn’s Disease 14.18.3. GERD 14.18.4. Others 14.19. Germany Gastrointestinal Therapeutics Market Forecast, by Distribution Channel 14.19.1. Hospital Pharmacies 14.19.2. Retail Pharmacies 14.19.3. Online Pharmacies 14.20. Russia Gastrointestinal Therapeutics Market Forecast, by Type 14.20.1. Branded 14.20.2. Generics 14.21. Russia Gastrointestinal Therapeutics Market Forecast, by Route of Administration 14.21.1. Oral 14.21.2. Intravenous 14.21.3. Others 14.22. Russia Gastrointestinal Therapeutics Market Forecast, by Application 14.22.1. Ulcerative Colitis 14.22.2. Crohn’s Disease 14.22.3. GERD 14.22.4. Others 14.23. Russia Gastrointestinal Therapeutics Market Forecast, by Distribution Channel 14.23.1. Hospital Pharmacies 14.23.2. Retail Pharmacies 14.23.3. Online Pharmacies 14.24. Italy Gastrointestinal Therapeutics Market Forecast, by Type 14.24.1. Branded 14.24.2. Generics 14.25. Italy Gastrointestinal Therapeutics Market Forecast, by Route of Administration 14.25.1. Oral 14.25.2. Intravenous 14.25.3. Others 14.26. Italy Gastrointestinal Therapeutics Market Forecast, by Application 14.26.1. Ulcerative Colitis 14.26.2. Crohn’s Disease 14.26.3. GERD 14.26.4. Others 14.27. Italy Gastrointestinal Therapeutics Market Forecast, by Distribution Channel 14.27.1. Hospital Pharmacies 14.27.2. Retail Pharmacies 14.27.3. Online Pharmacies 14.28. Rest of Europe Gastrointestinal Therapeutics Market Forecast, by Type 14.28.1. Branded 14.28.2. Generics 14.29. Rest of Europe Gastrointestinal Therapeutics Market Forecast, by Route of Administration 14.29.1. Oral 14.29.2. Intravenous 14.29.3. Others 14.30. Rest of Europe Gastrointestinal Therapeutics Market Forecast, by Application 14.30.1. Ulcerative Colitis 14.30.2. Crohn’s Disease 14.30.3. GERD 14.30.4. Others 14.31. Rest of Europe Gastrointestinal Therapeutics Market Forecast, by Distribution Channel 14.31.1. Hospital Pharmacies 14.31.2. Retail Pharmacies 14.31.3. Online Pharmacies 14.32. PEST Analysis 14.33. Key Trends 14.34. Key Developments 15. Asia-Pacific Gastrointestinal Therapeutics Market Analysis 15.1. Key Findings 15.2. Asia-Pacific Gastrointestinal Therapeutics Market Overview 15.3. Asia-Pacific Gastrointestinal Therapeutics Market Forecast, by Type 15.3.1. Branded 15.3.2. Generics 15.4. Asia-Pacific Gastrointestinal Therapeutics Market Forecast, by Route of Administration 15.4.1. Oral 15.4.2. Intravenous 15.4.3. Others 15.5. Asia-Pacific Gastrointestinal Therapeutics Market Forecast, by Application 15.5.1. Ulcerative Colitis 15.5.2. Crohn’s Disease 15.5.3. GERD 15.5.4. Others 15.6. Asia-Pacific Gastrointestinal Therapeutics Market Forecast, by Distribution Channel 15.6.1. Hospital Pharmacies 15.6.2. Retail Pharmacies 15.6.3. Online Pharmacies 15.7. Asia-Pacific Gastrointestinal Therapeutics Market Forecast, by Country 15.7.1. China 15.7.2. India 15.7.3. Japan 15.7.4. Malaysia 15.7.5. Indonesia 15.7.6. Rest of Asia-Pacific 15.8. China Gastrointestinal Therapeutics Market Forecast, by Type 15.8.1. Branded 15.8.2. Generics 15.9. China Gastrointestinal Therapeutics Market Forecast, by Route of Administration 15.9.1. Oral 15.9.2. Intravenous 15.9.3. Others 15.10. China Gastrointestinal Therapeutics Market Forecast, by Application 15.10.1. Ulcerative Colitis 15.10.2. Crohn’s Disease 15.10.3. GERD 15.10.4. Others 15.11. China Gastrointestinal Therapeutics Market Forecast, by Distribution Channel 15.11.1. Hospital Pharmacies 15.11.2. Retail Pharmacies 15.11.3. Online Pharmacies 15.12. India Gastrointestinal Therapeutics Market Forecast, by Type 15.12.1. Branded 15.12.2. Generics 15.13. India Gastrointestinal Therapeutics Market Forecast, by Route of Administration 15.13.1. Oral 15.13.2. Intravenous 15.13.3. Others 15.14. India Gastrointestinal Therapeutics Market Forecast, by Application 15.14.1. Ulcerative Colitis 15.14.2. Crohn’s Disease 15.14.3. GERD 15.14.4. Others 15.15. India Gastrointestinal Therapeutics Market Forecast, by Distribution Channel 15.15.1. Hospital Pharmacies 15.15.2. Retail Pharmacies 15.15.3. Online Pharmacies 15.16. Japan Gastrointestinal Therapeutics Market Forecast, by Type 15.16.1. Branded 15.16.2. Generics 15.17. Japan Gastrointestinal Therapeutics Market Forecast, by Route of Administration 15.17.1. Oral 15.17.2. Intravenous 15.17.3. Others 15.18. Japan Gastrointestinal Therapeutics Market Forecast, by Application 15.18.1. Ulcerative Colitis 15.18.2. Crohn’s Disease 15.18.3. GERD 15.18.4. Others 15.19. Japan Gastrointestinal Therapeutics Market Forecast, by Distribution Channel 15.19.1. Hospital Pharmacies 15.19.2. Retail Pharmacies 15.19.3. Online Pharmacies 15.20. Indonesia Gastrointestinal Therapeutics Market Forecast, by Type 15.20.1. Branded 15.20.2. Generics 15.21. Indonesia Gastrointestinal Therapeutics Market Forecast, by Route of Administration 15.21.1. Oral 15.21.2. Intravenous 15.21.3. Others 15.22. Indonesia Gastrointestinal Therapeutics Market Forecast, by Application 15.22.1. Ulcerative Colitis 15.22.2. Crohn’s Disease 15.22.3. GERD 15.22.4. Others 15.23. Indonesia Gastrointestinal Therapeutics Market Forecast, by Distribution Channel 15.23.1. Hospital Pharmacies 15.23.2. Retail Pharmacies 15.23.3. Online Pharmacies 15.24. Malaysia Gastrointestinal Therapeutics Market Forecast, by Type 15.24.1. Branded 15.24.2. Generics 15.25. Malaysia Gastrointestinal Therapeutics Market Forecast, by Route of Administration 15.25.1. Oral 15.25.2. Intravenous 15.25.3. Others 15.26. Malaysia Gastrointestinal Therapeutics Market Forecast, by Application 15.26.1. Ulcerative Colitis 15.26.2. Crohn’s Disease 15.26.3. GERD 15.26.4. Others 15.27. Malaysia Gastrointestinal Therapeutics Market Forecast, by Distribution Channel 15.27.1. Hospital Pharmacies 15.27.2. Retail Pharmacies 15.27.3. Online Pharmacies 15.28. Rest of Asia-Pacific Gastrointestinal Therapeutics Market Forecast, by Type 15.28.1. Branded 15.28.2. Generics 15.29. Rest of Asia-Pacific Gastrointestinal Therapeutics Market Forecast, by Route of Administration 15.29.1. Oral 15.29.2. Intravenous 15.29.3. Others 15.30. Rest of Asia-Pacific Gastrointestinal Therapeutics Market Forecast, by Application 15.30.1. Ulcerative Colitis 15.30.2. Crohn’s Disease 15.30.3. GERD 15.30.4. Others 15.31. Rest of Asia-Pacific Gastrointestinal Therapeutics Market Forecast, by Distribution Channel 15.31.1. Hospital Pharmacies 15.31.2. Retail Pharmacies 15.31.3. Online Pharmacies 15.32. PEST Analysis 15.33. Key Trends 15.34. Key Developments 16. MEA & Africa Gastrointestinal Therapeutics Market Analysis 16.1. Key Findings 16.2. MEA &Africa Gastrointestinal Therapeutics Market Overview 16.3. MEA &Africa Gastrointestinal Therapeutics Market Forecast, by Type 16.3.1. Branded 16.3.2. Generics 16.4. MEA &Africa Gastrointestinal Therapeutics Market Forecast, by Route of Administration 16.4.1. Oral 16.4.2. Intravenous 16.4.3. Others 16.5. MEA &Africa Gastrointestinal Therapeutics Market Forecast, by Application 16.5.1. Ulcerative Colitis 16.5.2. Crohn’s Disease 16.5.3. GERD 16.5.4. Others 16.6. MEA &Africa Gastrointestinal Therapeutics Market Forecast, by Distribution Channel 16.6.1. Hospital Pharmacies 16.6.2. Retail Pharmacies 16.6.3. Online Pharmacies 16.7. MEA &Africa Gastrointestinal Therapeutics Market Forecast, by Country 16.7.1. GCC 16.7.2. South Africa 16.7.3. Rest of MEA & Africa 16.8. GCC Gastrointestinal Therapeutics Market Forecast, by Type 16.8.1. Branded 16.8.2. Generics 16.9. GCC Gastrointestinal Therapeutics Market Forecast, by Route of Administration 16.9.1. Oral 16.9.2. Intravenous 16.9.3. Others 16.10. GCC Gastrointestinal Therapeutics Market Forecast, by Application 16.10.1. Ulcerative Colitis 16.10.2. Crohn’s Disease 16.10.3. GERD 16.10.4. Others 16.11. GCC Gastrointestinal Therapeutics Market Forecast, by Distribution Channel 16.11.1. Hospital Pharmacies 16.11.2. Retail Pharmacies 16.11.3. Online Pharmacies 16.12. South Africa Gastrointestinal Therapeutics Market Forecast, by Type 16.12.1. Branded 16.12.2. Generics 16.13. South Africa Gastrointestinal Therapeutics Market Forecast, by Route of Administration 16.13.1. Oral 16.13.2. Intravenous 16.13.3. Others 16.14. South Africa Gastrointestinal Therapeutics Market Forecast, by Application 16.14.1. Ulcerative Colitis 16.14.2. Crohn’s Disease 16.14.3. GERD 16.14.4. Others 16.15. South Africa Gastrointestinal Therapeutics Market Forecast, by Distribution Channel 16.15.1. Hospital Pharmacies 16.15.2. Retail Pharmacies 16.15.3. Online Pharmacies 16.16. Rest of MEA &Africa Gastrointestinal Therapeutics Market Forecast, by Type 16.16.1. Branded 16.16.2. Generics 16.17. Rest of MEA &Africa Gastrointestinal Therapeutics Market Forecast, by Route of Administration 16.17.1. Oral 16.17.2. Intravenous 16.17.3. Others 16.18. Rest of MEA &Africa Gastrointestinal Therapeutics Market Forecast, by Application 16.18.1. Ulcerative Colitis 16.18.2. Crohn’s Disease 16.18.3. GERD 16.18.4. Others 16.19. Rest of MEA &Africa Gastrointestinal Therapeutics Market Forecast, by Distribution Channel 16.19.1. Hospital Pharmacies 16.19.2. Retail Pharmacies 16.19.3. Online Pharmacies 16.20. PEST Analysis 16.21. Key Trends 16.22. Key Developments 17. Latin America Gastrointestinal Therapeutics Market Analysis 17.1. Key Findings 17.2. Latin America Gastrointestinal Therapeutics Market Overview 17.3. Latin America Gastrointestinal Therapeutics Market Forecast, by Type 17.3.1. Branded 17.3.2. Generics 17.4. Latin America Gastrointestinal Therapeutics Market Forecast, by Route of Administration 17.4.1. Oral 17.4.2. Intravenous 17.4.3. Others 17.5. Latin America Gastrointestinal Therapeutics Market Forecast, by Application 17.5.1. Ulcerative Colitis 17.5.2. Crohn’s Disease 17.5.3. GERD 17.5.4. Others 17.6. Latin America Gastrointestinal Therapeutics Market Forecast, by Distribution Channel 17.6.1. Hospital Pharmacies 17.6.2. Retail Pharmacies 17.6.3. Online Pharmacies 17.7. Latin America Gastrointestinal Therapeutics Market Forecast, by Country 17.7.1. Mexico 17.7.2. Brazil 17.7.3. Rest of Latin America 17.8. Mexico Gastrointestinal Therapeutics Market Forecast, by Type 17.8.1. Branded 17.8.2. Generics 17.9. Mexico Gastrointestinal Therapeutics Market Forecast, by Route of Administration 17.9.1. Oral 17.9.2. Intravenous 17.9.3. Others 17.10. Mexico Gastrointestinal Therapeutics Market Forecast, by Application 17.10.1. Ulcerative Colitis 17.10.2. Crohn’s Disease 17.10.3. GERD 17.10.4. Others 17.11. Mexico Gastrointestinal Therapeutics Market Forecast, by Distribution Channel 17.11.1. Hospital Pharmacies 17.11.2. Retail Pharmacies 17.11.3. Online Pharmacies 17.12. Brazil Gastrointestinal Therapeutics Market Forecast, by Type 17.12.1. Branded 17.12.2. Generics 17.13. Brazil Gastrointestinal Therapeutics Market Forecast, by Route of Administration 17.13.1. Oral 17.13.2. Intravenous 17.13.3. Others 17.14. Brazil Gastrointestinal Therapeutics Market Forecast, by Application 17.14.1. Ulcerative Colitis 17.14.2. Crohn’s Disease 17.14.3. GERD 17.14.4. Others 17.15. Brazil Gastrointestinal Therapeutics Market Forecast, by Distribution Channel 17.15.1. Hospital Pharmacies 17.15.2. Retail Pharmacies 17.15.3. Online Pharmacies 17.16. Rest of Latin America Gastrointestinal Therapeutics Market Forecast, by Type 17.16.1. Branded 17.16.2. Generics 17.17. Rest of Latin America Gastrointestinal Therapeutics Market Forecast, by Route of Administration 17.17.1. Oral 17.17.2. Intravenous 17.17.3. Others 17.18. Rest of Latin America Gastrointestinal Therapeutics Market Forecast, by Application 17.18.1. Ulcerative Colitis 17.18.2. Crohn’s Disease 17.18.3. GERD 17.18.4. Others 17.19. Rest of Latin America Gastrointestinal Therapeutics Market Forecast, by Distribution Channel 17.19.1. Hospital Pharmacies 17.19.2. Retail Pharmacies 17.19.3. Online Pharmacies 17.20. PEST Analysis 17.21. Key Trends 17.22. Key Developments 18. Company Profiles 18.1. Market Share Analysis, by Company 18.2. Market Share Analysis, by Region 18.3. Market Share Analysis, by Country 18.4. Competition Matrix 18.4.1. Competitive Benchmarking of key players by price, presence, Market share, Raw material and R&D investment 18.4.2. New Raw material Launches and Raw material Enhancements 18.4.2.1. Market Consolidation 18.4.2.2. M&A by Regions, Investment and Raw material 18.4.2.3. M&A Key Players, Forward Integration and Backward Integration 18.5. Company Profiles: Key Players 18.5.1. Abbott Laboratories 18.5.2. Allergan plc 18.5.3. AstraZeneca 18.5.4. Bayer AG 18.5.5. GlaxoSmithKline plc 18.5.6. Janssen Pharmaceuticals 18.5.7. Takeda Pharmaceuticals 18.5.8. Valeant Pharmaceuticals 18.5.9. Pfizer 18.5.10. AbbVie, Inc. 18.5.11. AstraZeneca 18.5.12. Shire 18.5.13. Valeant (Salix Pharmaceuticals) 18.5.14. Takeda Pharmaceutical Company Limited 18.5.15. Eisai Co. Ltd. 18.5.16. Johnson & Johnson Private Limited. 18.5.17. Astellas Pharma Inc. 18.5.18. Novo Nordisk A/S 18.5.19. Sanofi S.A. 19. Primary Key Insights.